Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001140361-26-017092
Filing Date
2026-04-27
Accepted
2026-04-27 16:10:45
Documents
3

Document Format Files

Seq Description Document Type Size
1 DEFA14A ef20071345_defa14a.htm DEFA14A 9842
2 image01.jpg GRAPHIC 499693
3 image02.jpg GRAPHIC 426795
  Complete submission text file 0001140361-26-017092.txt   1286356
Mailing Address 200 SIDNEY STREET CAMBRIDGE MA 02139
Business Address 200 SIDNEY STREET CAMBRIDGE MA 02139 617 945 9626
Seres Therapeutics, Inc. (Filer) CIK: 0001609809 (see all company filings)

EIN.: 274326290 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-37465 | Film No.: 26901003
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)